EirGenix Inc. (TPEX:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
62.80
+1.00 (1.62%)
Jun 12, 2025, 1:30 PM CST
-20.00%
Market Cap 18.68B
Revenue (ttm) 971.19M
Net Income (ttm) -751.42M
Shares Out 302.34M
EPS (ttm) -2.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 248,933
Average Volume 326,960
Open 62.40
Previous Close 61.80
Day's Range 62.10 - 63.20
52-Week Range 52.70 - 100.50
Beta 0.40
RSI 43.16
Earnings Date Aug 13, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements

News

There is no news available yet.